Market research
PRPO Precipio Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 56M
- P/E ratio
- Not available
- Analyst target
- 19
- Dividend yield
- Not available
- Beta
- 1.29
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- ISIN
- US74019L6020
- Market cap
- 56M
- P/E ratio
- Not available
- Analyst target
- 19
- Dividend yield
- Not available
- Beta
- 1.29
About
About Precipio Inc
Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers HemeScreen, a suite of robust genetic diagnostic panels; and IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages. It offers biomarker testing and clinical project services to bio-pharma customers. Precipio, Inc. is based in New Haven, Connecticut.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the PRPO discussion.
5 years, 4 months ago
Precipio, Inc is currently in a long term uptrend where the price is trading 17.6% above its 200 day moving average.
From a valuation standpoint, the stock is 99.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 6.4.
Precipio, Inc's total revenue rose by 344.8% to $3M since the same quarter in the previous year.
Its net income has increased by 100.0% to $-2K since the same quarter in the previous year.
Finally, its free cash flow grew by 31.0% to $-1M since the same quarter in the previous year.
Based on the above factors, Precipio, Inc gets an overall score of 5/5.